title: Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.
authors.affiliation: Division of Haematopathology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada. zxu@toh.on.ca.
authors.forename: Zhaodong
authors.initials: Z
authors.lastname: Xu
authors.forename: Luke
authors.initials: L
authors.lastname: Shier
authors.forename: Mitchell
authors.initials: M
authors.lastname: Sabloff
authors.forename: Arleigh
authors.initials: A
authors.lastname: McCurdy
authors.forename: Dawn
authors.initials: D
authors.lastname: Sheppard
authors.forename: Christopher
authors.initials: C
authors.lastname: Bredeson
mesh_terms: D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy* / Q000473:pathology; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001374:Azacitidine / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D034721:Mastocytosis, Systemic / Q000139:chemically induced* / Q000473:pathology
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine